Maegim한국어

테라젠이텍스

066700KOSDAQSector: Pharma & Biotech
₩1,929▲ 2.17%Market cap ₩71.7BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.8 ptsTop 14% of 2,523 stocks
Financial strength
60.2
Growth momentum
52.1
Price attractiveness
90.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

60.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
61.9%
✗ Below median · Top 57.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
194.7%
✓ Above median · Top 47.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.8%
✓ Above median · Top 32.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
7.6%
✓ Above median · Top 20.9% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

52.1
How much did revenue grow in a year?
Revenue growth (YoY)
8.8%
✓ Above median · Top 41.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
12.0%
✓ Above median · Top 26.1% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-18.3%
✗ Below median · Top 70.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-1.3%
✗ Below median · Top 53.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

90.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
6.8x
✓ Above median · Top 6.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.52x
✓ Above median · Top 12.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15